Upcoming ONCY public events... Im looking at the next two clinical trial events as ones that will give critical updates to the efficacy. Two Phase I(s) and One Phase II. Sarcoma cancers are very difficult to treat. Most of ONCY's clinical trials only include those who are refractory to standard treatments so any clinical responses are very interesting IMO.
------------
BioInvestor Forum - San Francisco, CA
Oct 29-31 (Oct 29th today at 2:15pm Pacific Daylight Time)
iSBTc - San Diego, CA
Dr. Harrington poster - Carboplatin and Paclitaxel combo Phase I (REO-011)
Dr. Pandha - Docetaxel combo Phase I (REO-010)
Oct 31-Nov 1
Chemo Foundation Symposium - New York, NY
Dr. Mita et al - Oral Presentation Phase II Sarcoma (REO-014)
Nov 4-8
Rodman & Renshaw Annual Global Investment Conference
Nov 11th
CTOS - London, UK
Dr Mita et al - Oral Presentation Phase II Sarcoma
Dr. Kolb - poster Cisplatin and Radiation Sarcoma Xenographs
Nov 13-15
BioPartnering North America - Vancouver, BC
Feb 8-10
--------
Previously Dr Harrington reported on the combo Paclitaxel/Carboplatin study (REO 011) in April 9th ...
4/9/2008 11:19:58 AM ET News Release Index
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN® and Carboplatin/Paclitaxel Trial
CALGARY, AB, --- April 9, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced positive interim results from its U.K. combination REOLYSIN® and carboplatin/paclitaxel trial. Dr. Kevin Harrington of The Institute of Cancer Research, London, and the principal investigator for the trial, presented the results today at The 5th Annual Conference of the British Society for Gene Therapy (BSGT) in Edinburgh, Scotland.
Four of the first eight patients treated in the study to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients evaluated to date have had excellent clinical and radiological responses without appreciable toxicity. Preliminary assessment after recruitment of the first two cohorts has suggested that patients with head and neck carcinomas may represent a group of patients in whom the combination of carboplatin/paclitaxel and REOLYSIN® is active.
“These early results in head and neck patients are remarkable, considering the prognosis for refractory patients is generally poor,” said Dr. Karl Mettinger, Chief Medical Officer for Oncolytics.
In the first cohort, the patient with head and neck cancer received 8 cycles of treatment (the maximum allowed) and achieved a clinical complete response. In the second cohort, the two patients with head and neck cancers with widespread disseminated disease have each received six cycles of treatment to date and both have achieved significant partial responses. Two of the three patients, including the patient with the clinical complete response, had previously received cisplatin/5-FU treatment and all three had previously received radiotherapy.
-------
Previously Dr Pandha has not reported on interim results so this is the first look.
-------
Previously Dr Mita has published interim results on REO-014 on June 2nd at ASCO
6/2/2008 2:00:00 AM ET News Release Index
Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
CALGARY, AB, --- June 2, 2008 – Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung were presented yesterday at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation, entitled “A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung” was delivered by Dr. Monica Mita, the study principal investigator and her team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.
The interim results demonstrate that the treatment has been well tolerated to date, with 8 of 16 evaluable patients experiencing stable disease for periods ranging from two to more than ten, 28-day cycles. As previously announced by Oncolytics, the third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time showed that any residual mass was metabolically inert.
“These very encouraging data have increased our commitment to the thorough investigation of this exciting, unique, truly targeted agent,” said Dr Francis Giles, Director of the IDD at UTHSC.
“We feel privileged to participate in this study and to be able to offer this therapeutic option to our patients,” said Dr. Mita. “Patients have tolerated the treatment well and seem to have disease control up to several months, which is encouraging for patients with advanced refractory sarcoma.”
onco_investor
